Is tamoxifen a genotoxic carcinogen in women?

Mutagenesis

Volumn 24, Issue 5, 2009, Pages 391-404

  Brown, Karen ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE; SULFATE; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; BREAST CANCER; CARCINOGENICITY; DNA ADDUCT; DRUG ACTIVATION; DRUG DNA BINDING; DRUG STRUCTURE; ENDOMETRIUM CANCER; FEMALE; GENOTOXICITY; HUMAN; HUMAN CELL; HYDROXYLATION; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; RISK BENEFIT ANALYSIS;

ANIMALS; CARCINOGENS; CHEMOPREVENTION; DNA ADDUCTS; DNA DAMAGE; FEMALE; HUMANS; TAMOXIFEN;

RATTUS;

EID: 71949101735     PISSN: 02678357     EISSN: 14643804     Source Type: Journal    
DOI: 10.1093/mutage/gep022     Document Type: Review

References (152)

1. Cole, M. P., Jones, C. T. A. and Todd, I. D. H. (1971) New antioestrogenic agent in late breast cancer-early clinical appraisal of ICI46474. Br. J. Cancer, 25, 270-275.
2. White, I. N. H. (1999) The tamoxifen dilemma. Carcinogenesis, 20, 1153-1160.
3. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 365, 1687-1717.
4. Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet, 351, 1451-1467.
5. Jordan, V. C. (1993) A current view of tamoxifen for the treatment and prevention of breast cancer. Br. J. Pharmacol., 110, 507-517.
6. McDonald, C. C., Alexander, F. E., Whyte, B. W., Forrest, A. P. and Stewart, H. J. (1995) Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast-cancer in a randomised trial.BMJ, 311, 977-980.
7. Costantino, J. P., Kuller, L. H., Ives, D. G., Fisher, B. and Dignam, J. (1997) Coronary heart disease mortality and adjuvant tamoxifen therapy. J. Natl Cancer Inst., 89, 776-782.
8. Love, R. R., Mazess, R. B. and Barden, H. S. (1992) Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N. Engl. J. Med., 326, 852-856.
9. Fisher, B., Costantino, J. P., Wickerham, D. L. et al. (1998) Tamoxifen for the prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst., 90, 1371-1388. (Pubitemid 28439961)
10. Mandeville, R. and Houde, M. (1994) A critical review of the potential carcinogenicity of tamoxifen on steroid hormone-sensitive tissues. Cancer J., 7, 12-19.
11. Shang, Y. and Brown, M. (2002) Molecular determinants for the tissue specificity of SERMs. Science, 295, 2465-2468.
12. Jordan, V.C. (1976) Effect of tamoxifen (ICI 46, 474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur. J. Cancer, 12, 419-424.
13. Gottardis, M. M. and Jordan, V. C. (1987) Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res., 47, 4020-4024.
14. Jordan, V. C., Lababidi, M. K. and Langanfahey, S. (1991) Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J. Natl Cancer Inst., 83, 492-496.
15. Liehr, J. G., Sirbasku, D. A., Jurka, E., Randerath, K. and Randerath, E. (1988) Inhibition of estrogen-induced renal carcinogenesis in male Syrianhamsters by tamoxifen without decrease in DNA adduct levels. Cancer Res., 48, 779-783.
16. Powles, T. J. (1992) The case for clinical trials of tamoxifen for prevention of breast cancer. Lancet, 340, 1145-1147.
17. Powles, T. J., Jones, A. L., Ashley, S. E. et al. (1994) The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res. Treat., 31, 73-82.
18. Powles, T. J., Hardy, J. R., Ashley, S. E. et al. (1989) A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br. J. Cancer, 60, 126-131.
19. Veronesi, U., Maisonneuve, P., Costa, A., Sacchini, V., Maltoni, C., Robertson, C., Rotmensz, N. and Boyle, P. (1998) Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian trial among hysterectomised women. Lancet, 352, 93-97.
20. Powles, T., Eeles, R., Ashley, S., Easton, D., Chang, J., Dowsett, M., Tidy, A., Viggers, J. and Davey, J. (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet, 352, 98-101.
21. Cuzick, J., Powles, T., Veronesi, U., Forbes, J., Edwards, R., Ashley, S. and Boyle, P. (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet, 361, 296-300.
22. Powles, T. J., Ashley, S., Tidy, A., Smith, I. E. andDowsett, M. (2007) Twentyyear follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J. Natl Cancer Inst., 99, 283-290.
23. Cuzick, J., Forbes, J. F., Sestak, I., Cawthorn, S., Hamed, H., Holli, K. and Howell, A. (2007) Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J. Natl Cancer Inst., 99, 272-282.
24. Shen, Y., Costantino, J. P. and Qin, J. (2008) Tamoxifen chemoprevention treatment and time to first diagnosis of estrogen receptor-negative breast cancer. J. Natl Cancer Inst., 100, 1448-1453.
25. Freedman, A. N., Graubard, B. I., Rao, S. R., McCaskill-Stevens, W., Ballard-Barbash, R. and Gail, M. H. (2003) Estimates of the number of U.S. women who could benefit from tamoxifen for breast cancer chemoprevention. J. Natl Cancer Inst., 95, 526-532.
26. Fisher, B., Costantino, J. P., Redmond, C. K. et al. (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NASBP)B-14. J. Natl Cancer. Inst., 86, 527-537. (Pubitemid 24111008)
27. Gottardis, M. M., Robinson, S. P., Satyaswaroop, P. G. and Jordan, V. C. (1988) Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res., 48, 812-815.
28. Fornander, T., Cedermark, B., Mattsson, A. et al. (1989) Adjuvant tamoxifen in early breast-cancer-occurrence of new primary cancers. Lancet, 1, 117-120.
29. Rutqvist, L. E., Johansson, H., Signomklao, T., Johansson, U., Fornander, T. and Wilking, N. (1995) Adjuvant tamoxifen therapy for early stage breast cancer and secondary primary malignancies. J. Natl Cancer Inst., 87, 645-651.
30. Curtis, R. E., Boice, J. D., Shriner, D. A., Hankey, B. F. and Fraumeni, J. F. (1996) Second cancers after adjuvant tamoxifen therapy for breast cancer. J. Natl Cancer Inst., 88, 832-834.
31. Magriples, U., Naftolin, F., Schwartz, P. E. and Carcangiu, M. L. (1993) High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J. Clin. Oncol., 11, 485-490.
32. Brown, K. (2002) Breast cancer chemoprevention: Risk-benefit effects of the anti-oestrogen tamoxifen. Expert Opin. Drug Saf., 1, 253-267.
33. Jordan, V. C. (2003) Tamoxifen: a most unlikely pioneering medicine. Nat. Rev. Drug Dis., 2, 205-213.
34. Carthew, P., Rich, K. J., Martin, E. A., De Matteis, F., Lim, C. K., Manson, M. M., Festing, M. F. W., White, I. N. H. and Smith, L. L. (1995) DNA damage as assessed by 32P-postlabelling in three rat strains exposed to dietary tamoxifen: The relationship between cell proliferation and liver tumour formation. Carcinogenesis, 16, 1299-1304.
35. Williams, G. M., Iatropoulos, M. J., Djordjevic, M. V. and Kaltenberg, O. P. (1993) The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis, 14, 315-317.
36. Greaves, P., Goonetilleke, R., Nunn, G., Topham, J. and Orton, T. (1993) Two-year carcinogenicity study of tamoxifen in Alderley Park Wistarderived rats. Cancer Res., 53, 3919-3924.
37. Tucker, M. J., Adams, H. K. and Patterson, J. S. (1984) Tamoxifen. In Laurence, D. R., McLean, A. E. M. and Weatherall, M. (eds), Safety Testing of New Drugs. Academic Press, New York, pp. 125-161.
38. Martin, E. A., Carthew, P., White, I. N. H., Heydon, R. T., Gaskell, M., Mauthe, R. J., Turteltaub, K. W. and Smith, L. L. (1997) Investigation of the formation and accumulation of liver DNA adducts in mice chronically exposed to tamoxifen. Carcinogenesis, 18, 2209-2215.
39. Hard, G. C., Iatropoulos, M. J., Jordan, K., Radi, L., Kaltenberg, O. P., Imondi, A. R. and Willilams, G. M. (1993) Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res., 53, 4534-4541.
40. Williams, G. M., Iatropoulos, M. J. and Karlsson, S. (1997) Initiating effects of the anti-estrogen tamoxifen, but not toremifene in rat liver. Carcinogenesis, 18, 2247-2253.
41. Carthew, P., Martin, E. A., White, I. N. H., De Matteis, F., Edwards, R. E., Dorman, B. M., Heydon, R. T. and Smith, L. L. (1995) Tamoxifen induces short-term cumulative DNA damage and liver tumors in rats: Promotion by phenobarbital. Cancer Res., 55, 544-547.
42. Mühlemann, K., Cook, L. S. and Weiss, N. S. (1994) The incidence of hepatocellular carcinoma in US white women with breast cancer after the introduction of tamoxifen in 1977. Breast Cancer Res. Treat., 30, 201-204.
43. Stearns, V. and Gelmann, E. P. (1998) Does tamoxifen cause cancer in humans? J. Clin. Oncol., 16, 779-792.
44. Ryden, S., Ferno, M., Moller, T., Aspegren, K., Bergljung, L., Killander, D. and Landberg, T. (1992) Long-term effects of adjuvant tamoxifen and/or radiotherapy. The South Sweden Breast Cancer Trial. Acta Oncol., 31, 271-274.
45. Newcomb, P. A., Solomon, C. and White, E. (1999) Tamoxifen and risk of large bowel cancer in women with breast cancer. Breast Cancer Res. Treat., 53, 271-277.
46. Andersson, M., Storm, H. H. and Mouridsen, H. T. (1991) Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J. Natl Cancer Inst., 83, 1013-1017.
47. Braithwaite, R. S., Chlebowski, R. T., Lau, J., George, S., Hess, R. and Col, N. F. (2003) Meta-analysis of vascular and neoplastic events associated with tamoxifen. J. Gen. Intern. Med., 18, 937-947.
48. Tamoxifen. Some Pharmaceutical Drugs. IARC, Lyon, France, 253-365.
49. Prat, J., Gallardo, A., Cuatrecasas, M. and Catasús, L. (2007) Endometrial carcinoma: Pathology and genetics. Pathology, 39, 72-87.
50. Ferguson, S. E., Soslow, R. A., Amsterdam, A. and Barakat, R. R. (2006) Comparison of uterine malignancies that develop during and following tamoxifen therapy. Gynecol. Oncol., 101, 322-326.
51. Singh, M. N., Stringfellow, H. F., Paraskevaidis, E., Martin-Hirsch, P. L. and Martin, F. L. (2007) Tamoxifen: Important considerations of a multifunctional compound with organ-specific properties. Cancer Treat. Rev., 33, 91-100.
52. Han, X. and Liehr, J. G. (1992) Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res., 52, 1360-1363.
53. Carthew, P., Lee, P. N., Edwards, R. E., Heydon, R. T., Nolan, B. M. and Martin, E. A. (2001) Cumulative exposure to tamoxifen: DNA adducts and liver cancer in the rat. Arch. Toxicol, 75, 375-380.
54. Martin, E. A., Heydon, R. T., Brown, K., Brown, J. E., Lim, C. K., White, I. N. H. and Smith, L. L. (1998) Evaluation of tamoxifen and a-hydroxytamoxifen 32P-post-labelled DNA adducts by the development of a novel automated on-line solid-phase extraction HPLC method. Carcinogenesis, 19, 1061-1069.
55. White, I. N. H., de Matteis, F., Davies, A., Smith, L. L., Croftonsleigh, C., Venitt, S., Hewer, A. and Phillips, D. H. (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis, 13, 2197-2203.
56. Phillips, D. H., Hewer, A., Osborne, M. R., Cole, K. J., Churchill, C. and Arlt, V. M. (2005) Organ specificity of DNA adduct formation by tamoxifen and a-hydroxytamoxifen in the rat: Implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment. Mutagenesis, 20, 297-303.
57. Beland, F. A., McDaniel, L. P. and Marques, M. M. (1999) Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo. Carcinogenesis, 20, 471-477.
58. Brown, K., Brown, J. E., Martin, E. A., Smith, L. L. and White, I. N. H. (1998) Determination of DNA damage in F344 rats induced by geometric isomers of tamoxifen and analogues. Chem. Res. Toxicol., 11, 527-534.
59. Styles, J. A., Davies, A., Lim, C. K., de Matteis, F., Stanley, L. A., White, I. N. H., Yuan, Z. X. and Smith, L. L. (1994) Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis, 15, 5-9. (Pubitemid 24121616)
60. Sargent, L. M., Dragan, Y. P., Bahnub, N., Wiley, J. E., Sattler, C. A., Schroeder, P., Sattler, G. L., Jordan, V. C. and Pitot, H. C. (1994) Tamoxifen induces hepatic aneuploidy and mitotic spindle disruption after a single in vivo administration to female Sprague-Dawley rats. Cancer Res., 54, 3357-3360.
61. Davies, R., Oreffo, V. I. C., Martin, E. A., Festing, M. F. W., White, I. N. H., Smith, L. L. and Styles, J. A. (1997) Tamoxifen causes gene mutations in the livers of Lambda/lacI transgenic rats. Cancer Res., 57, 1288-1293.
62. Davies, R., Gant, T. W., Smith, L. L. and Styles, J. A. (1999) Tamoxifen induces G:C/T:A mutations in the cII gene in the liver of lambda/lacI transgenic rats but not at 5#-CpG#3# dinucleotide sequences as found in the lacI transgene. Carcinogenesis, 20, 1351-1356.
63. Davies, R., Oreffo, V. I. C., Bayliss, S., Dinh, P. A., Lilley, K. S., White, I. N. H., Smith, L. L. and Styles, J. A. (1996) Mutational spectra of tamoxifen-induced mutations in the livers of lacl transgenic rats. Environ. Mol. Mutagen., 28, 430-433.
64. Vancutsem, P. M., Lazarus, P. and Williams, G. M. (1994) Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen. Cancer Res., 54, 3864-3867.
65. Chen, T., Gamboa da Costa, G., Marques, M. M., Shelton, S. D., Beland, F. A. and Manjanatha, M. G. (2002) Mutations induced by a-hydroxytamoxifen in the lacI and cII genes of Big Blue transgenic rats. Carcinogenesis, 23, 1751-1757.
66. Gamboa da Costa, G., McDaniel-Hamilton, L. P., Heflich, R. H., Marques, M. M. and Beland, F. A. (2001) DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives. Carcinogenesis, 22, 1307-1315.
67. Gamboa da Costa, G., Manjanatha, M. G., Marques, M. M. and Beland, F. A. (2002) Induction of lacI mutations in Big Blue rats treated with tamoxifen and a-hydroxytamoxifen. Cancer Lett., 176, 37-45.
68. Tryndyak, V. P., Kovalchuk, O., Muskhelishvili, L., Montgomery, B., Rodriguez-Juarez, R., Melnyk, S., Ross, S. A., Beland, F. A. and Pogribny, I. P. (2007) Epigenetic reprogramming of liver cells in tamoxifen-induced rat hepatocarcinogenesis. Mol. Carcinog., 46, 187-197.
69. Tryndyak, V. P., Muskhelishvili, L., Kovalchuk, O., Rodriguez-Juarez, R., Montgomery, B., Churchwell, M. I., Ross, S. A., Beland, F. A. and Pogribny, I. P. (2006) Effect of long-term tamoxifen exposure on genotoxic and epigenetic changes in rat liver: Implications for tamoxifeninduced hepatocarcinogenesis. Carcinogenesis, 27, 1713-1720.
70. Pogribny, I. P., Bagnyukova, T. V., Tryndyak, V. P. et al. (2007) Gene expression profiling reveals underlying molecular mechanisms of the early stages of tamoxifen-induced rat hepatocarcinogenesis. Toxicol. Appl. Pharmacol., 225, 61-69.
71. Phillips, D. H., Hewer, A., White, I. N. H. and Farmer, P. B. (1994) Cochromatography of a tamoxifen epoxide deoxyguanylic acid adduct with a major DNA adduct formed in the livers of tamoxifen-treated rats. Carcinogenesis, 15, 793-795. (Pubitemid 24156870)
72. Osborne, M. R., Hewer, A., Hardcastle, I. R., Carmichael, P. L. and Phillips, D. H. (1996) Identification of the major tamoxifendeoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res., 56, 66-71.
73. Moorthy, B., Sriram, P., Pathak, D. N., Bodell, W. J. and Randerath, K. (1996) Tamoxifen metabolic activation: Comparison of DNA adducts formed by microsomal and chemical activation of tamoxifen and 4- hydroxytamoxifen with DNA adducts formed in vivo. Cancer Res., 56, 53-57.
74. Pathak, D. N., Pongracz, K. and Bodell, W. J. (1995) Microsomal and peroxidase activation of 4-hydroxy-tamoxifen to form DNA adducts: Comparison with DNA adducts formed in Sprague-Dawley rats treated with tamoxifen. Carcinogenesis, 16, 11-15.
75. Marques, M. M. and Beland, F. A. (1997) Identification of tamoxifen- DNA adducts formed by 4-hydroxytamoxifen quinone methide. Carcinogenesis, 18, 1949-1954.
76. Zhang, F., Fan, P. W., Liu, X., Shen, L., van Breemen, R. B. and Bolton, J. L. (2000) Synthesis and reactivity of a potential carcinogenic metabolite of tamoxifen: 3, 4-dihydrotamoxifen-o-quinone. Chem. Res. Toxicol., 13, 53-62.
77. Sauvez, F., Drouin, D. S., Attia, M., Bertheux, H. and Forster, R. (1999) Cutaneously applied 4-hydroxytamoxifen is not carcinogenic in female rats. Carcinogenesis, 20, 843-850.
78. Phillips, D. H. (2001) Understanding the genotoxicity of tamoxifen? Carcinogenesis, 22, 839-849.
79. Poon, G. K., Walter, B., Lønning, P. E., Horton, M. N. and McCague, R. (1995) Identification of tamoxifen metabolites in human HEP G2 cell line, human liver homogenate and patients on long-term therapy for breast cancer. Drug Metab. Dispos., 23, 377-382.
80. Potter, G. A., McCague, R. and Jarman, M. (1994) A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. Carcinogenesis, 15, 439-442. (Pubitemid 24121688)
81. Phillips, D. H., Miller, J.A., Miller, E. C. and Adams, B. (1981) Structures of the DNA adducts formed inmouse liver after administration of the proximate hepatocarcinogen 1#-hydroxyestragole. Cancer Res., 41, 176-186.
82. Miller, J. A. and Miller, E. C. (1983) The metabolic activation and nucleic-acid adducts of naturally occurring carcinogens-recent results with ethyl carbamate and the spice flavours safrole and estragole. Br. J. Cancer, 48, 1-15.
83. Guenthner, T. M. and Luo, G. (2001) Investigation of the role of the 2#, 3#- epoxidation pathway in the bioactivation and genotoxicity of dietary alkylbenzene analogs. Toxicology, 160, 47-58.
84. Phillips, D. H., Potter, G. A., Horton, M. N., Hewer, A., Croftonsleigh, C., Jarman, M. and Venitt, S. (1994) Reduced genotoxicity of [D5-ethyl]- tamoxifen implicatesa-hydroxylation of the ethyl group as amajor pathway of tamoxifen activation to a liver carcinogen. Carcinogenesis, 15, 1487-1492.
85. Jarman, M., Poon, G. K., Rowlands, M. G., Grimshaw, R. M., Horton, M. N., Potter, G. A. and McCague, R. (1995) The deuterium isotope effect for the a-hydroxylation of tamoxifen by rat liver microsomes accounts for the reduced genotoxicity of [D5-ethyl]tamoxifen. Carcinogenesis, 16, 683-688.
86. Phillips, D. H., Carmichael, P. L., Hewer, A., Cole, K. J., Hardcastle, I. R., Poon, G. K., Keough, A. and Strain, A. J. (1996) Activation of tamoxifen and its metabolite a-hydroxytamoxifen to DNA-binding products: Comparison between human, rat and mouse hepatocytes. Carcinogenesis, 17, 89-94.
87. Dasaradhi, L. and Shibutani, S. (1997) Identification of tamoxifen-DNA adducts formed by a-sulfate tamoxifen and a-acetoxytamoxifen. Chem. Res. Toxicol., 10, 189-196.
88. Davis, W., Venitt, S. and Phillips, D. H. (1998) The metabolic activation of tamoxifen and a-hydroxytamoxifen to DNA-binding species in rat hepatocytes proceeds via sulphation. Carcinogenesis, 19, 861-866. (Pubitemid 28376779)
89. Glatt, H., Davis, W., Meinl, W., Hermersdorfer, H., Venitt, S. and Phillips, D. H. (1998) Rat, but not human, sulfotransferase activates a tamoxifen metabolite to produce DNA adducts and gene mutations in bacteria and mammalian cells in culture. Carcinogenesis, 19, 1709-1713.
90. Shibutani, S., Dasaradhi, L., Terashima, I., Banoglu, E. and Duffel, M. W. (1998) a-Hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts. Cancer Res., 58, 647-653.
91. Osborne, M. R., Hardcastle, I. R. and Phillips, D. H. (1997) Minor products of reaction with a-acetoxytamoxifen. Carcinogenesis, 18, 539-543.
92. Rajaniemi, H., Rasanen, I., Koivisto, P., Peltonen, K. and Hemminki, K. (1999) Identification of the major tamoxifen-DNA adduct in rat liver by mass spectrometry. Carcinogenesis, 20, 305-309.
93. Phillips, D. H., Hewer, A., Horton, M. N., Cole, K. J., Carmichael, P. L., Davis, W. and Osborne, M. R. (1999) N-Demethylation accompanies a-hydroxylation in the metabolic activation of tamoxifen in rat liver cells. Carcinogenesis, 20, 2003-2009.
94. Brown, K., Heydon, R. T., Jukes, R., White, I. N. H. and Martin, E. A. (1999) Further characterisation of the DNA adducts formed in rat liver after the administration of tamoxifen, N-desmethyltamoxifen or N, Ndidesmethyltamoxifen. Carcinogenesis, 20, 2011-2016.
95. Gamboa da Costa, G., Marques, M. M., Freeman, J. P. and Beland, F. A. (2003) Synthesis and investigation of a-hydroxy-N, N-didesmethyltamoxifen as a proximate carcinogen in the metabolic activation of tamoxifen. Chem. Res. Toxicol., 16, 1090-1098.
96. Hashiba, M., Kasahara, T., Kim, S. Y., Shibutani, S. and Degawa, M. (2006) DNA damage and altered gene expression of enzymes for metabolism and DNA repair by tamoxifen and toremifene in the female rat liver. Cancer Sci., 97, 468-477.
97. Umemoto, A., Monden, Y., Suwa, M. et al. (2000) Identification of hepatic tamoxifen-DNA adducts in mice: a-(N2-deoxyguanosinyl)tamoxifen and a-(N2-deoxyguanosinyl)tamoxifen N-oxide. Carcinogenesis, 21, 1737-1744.
98. Umemoto, A., Komaki, K., Monden, Y. et al. (2001) Identification and quantification of tamoxifen-DNA adducts in the liver of rats and mice. Chem. Res. Toxicol., 14, 1006-1013.
99. Hardcastle, I. R., Horton, M. N., Osborne, M. R., Hewer, A., Jarman, M. and Phillips, D. H. (1998) Synthesis and DNA reactivity of ahydroxylated metabolites of nonsteroidal antiestrogens. Chem. Res. Toxicol., 11, 369-374.
100. Boocock, D. J., Brown, K., Gibbs, A. H., Sanchez, E., Turteltaub, K. W. and White, I. N. H. (2002) Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis, 23, 1897-1901.
101. Kim, S. Y., Suzuki, N., Laxmi, Y. R. S., Rieger, R. and Shibutani, S. (2003) a-Hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes. Chem. Res. Toxicol., 16, 1138-1144.
102. Notley, L. M., Crewe, K. H., Taylor, P. J., Lennard, M. S. and Gillam, E. M. J. (2005) Characterization of the human cytochrome P450 forms involved in metabolism of tamoxifen to its a-hydroxy and a, 4- dihydroxy derivatives. Chem. Res. Toxicol., 18, 1611-1618.
103. Mahadevan, B., Arora, V., Schild, L. J. et al. (2006) Reduction in tamoxifen-induced CYP3A2 expression and DNA adducts using antisense technology. Mol. Carcinog., 45, 118-125.
104. Boocock, D. J., Maggs, J. L., White, I. N. H. and Park, B. K. (1999) a- Hydroxytamoxifen, a genotoxic metabolite of tamoxifen in the rat: Identification and quantification in vivo and in vitro. Carcinogenesis, 20, 153-160.
105. Boocock, D. J., Maggs, J. L., Brown, K., White, I. N. H. and Park, B. K. (2000) Major inter-species differences in the rates of O-sulphonation and O-glucuronylation of a-hydroxytamoxifen in vitro: a metabolic disparity protecting human liver from the formation of tamoxifen-DNA adducts. Carcinogenesis, 21, 1851-1858.
106. Shibutani, S., Shaw, P. M., Suzuki, N., Dasaradhi, L., Duffel, M. W. and Terashima, I. (1998) Sulfation of a-hydroxytamoxifen catalysed by human hydroxysteroid sulfotransferase results in tamoxifen-DNA adducts. Carcinogenesis, 19, 2007-2011.
107. Carmichael, P. L., Sardar, S., Crooks, N. et al. (1999) Lack of evidence from HPLC-32P-post-labelling for tamoxifen DNA adducts in the human endometrium. Carcinogenesis, 20, 339-342.
108. Carmichael, P. L., Ugwumadu, A. H., Neven, P., Hewer, A. J., Poon, G. K. and Phillips, D. H. (1996) Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res., 56, 1475-1479.
109. Martin, E. A., Rich, K. J., White, I. N. H., Woods, K. L., Powles, T. J. and Smith, L. L. (1995) 32P-postlabeled DNA-adducts in liver obtained from women treated with tamoxifen. Carcinogenesis, 16, 1651-1654.
110. Bartsch, H., Phillips, D. H., Nair, J., Hewer, A., Meyberg-Solomeyer, G. and Grischke, E. M. (2000) Lack of evidence for tamoxifen- and toremifene-DNA adducts in lymphocytes of treated patients. Carcinogenesis, 21, 845-847.
111. Beland, F. A., Churchwell, M. I., Doerge, D. R. et al. (2004) Electrospray ionization-tandem mass spectrometry and 32P-postlabeling analyses of tamoxifen-DNA adducts in humans. J. Natl Cancer Inst., 96, 1099-1104.
112. Shibutani, S., Suzuki, N., Terashima, I., Sugarman, S. M., Grollman, A. P. and Pearl, M. L. (1999) Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen. Chem. Res. Toxicol., 12, 646-653.
113. Shibutani, S., Ravindernath, A., Suzuki, N., Terashima, I., Sugarman, S. M., Grollman, A. P. and Pearl, M. L. (2000) Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis, 21, 1461-1467.
114. Umemoto, A., Monden, Y., Lin, C. X., Momen, A., Ueyama, Y., Komaki, K., Laxmi, Y. R. S. and Shibutani, S. (2004) Determination of tamoxifen-DNA adducts in leukocytes from breast cancer patients treated with tamoxifen. Chem. Res. Toxicol., 17, 1577-1583.
115. Hemminki, K., Rajaniemi, H., Lindahl, B. and Moberger, B. (1996) Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res., 56, 4374-4377.
116. Hemminki, K., Rajaniemi, H., Koskinen, M. and Hansson, J. (1997) Tamoxifen-induced DNA adducts in leucocytes of breast cancer patients. Carcinogenesis, 18, 9-13.
117. Orton, T. C. and Topham, J. C. (1997) Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res., 57, 4148-4148
118. Schild, L. J., Divi, R. L., Beland, F. A., Churchwell, M. I., Doerge, D. R., da Costa, G. G., Marques, M. M. and Poirier, M. C. (2003) Formation of tamoxifen-DNA adducts in multiple organs of adult female cynomolgus monkeys dosed with tamoxifen for 30 days. Cancer Res., 63, 5999-6003.
119. Phillips, D. H., Hewer, A., Grover, P. L., Poon, G. K. and Carmichael, P. L. (1996) Tamoxifen does not form detectable DNA adducts in white blood cells of breast cancer patients. Carcinogenesis, 17, 1149-1152.
120. Shibutani, S., Suzuki, N., Laxmi, Y. R. S., Schild, L. J., Divi, R. L., Grollman, A. P. and Poirier, M. C. (2003) Identification of tamoxifen- DNA adducts in monkeys treated with tamoxifen. Cancer Res., 63, 4402-4406.
121. Singh, M. N., Stringfellow, H. F., Walsh, M. J., Ashton, K. M., Paraskevaidis, E., Abdo, K. R., Martin-Hirsch, P. L., Phillips, D. H. and Martin, F. L. (2008) Quantifiable mRNA transcripts for tamoxifenmetabolising enzymes in human endometrium. Toxicology, 249, 85-90.
122. Brown, K., Tompkins, E. M. and White, I. N. H. (2006) Applications of accelerator mass spectrometry for pharmacological and toxicological research. Mass Spec. Rev., 25, 127-145.
123. White, I. N. H. and Brown, K. (2004) The application of accelerator mass spectrometry to pharmacology and toxicology. Trends Pharmacol. Sci., 25, 442-447.
124. Martin, E. A., Brown, K., Gaskell, M. et al. (2003) Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry. Cancer Res., 63, 8461-8465.
125. Brown, K., Tompkins, E. M., Boocock, D. J. et al. (2007) Tamoxifen forms DNA adducts in human colon after administration of a single [14C]- labeled therapeutic dose. Cancer Res., 67, 6995-7002.
126. Dingley, K. H., Curtis, K. D., Nowell, S., Felton, J. S., Lang, N. P. and Turteltaub, K. W. (1999) DNA and protein adduct formation in the colon and blood of humans after exposure to a dietary-relevant dose of 2-amino- 1-methyl-6-phenylimidazo[4, 5-b]pyridine. Cancer Epidemiol. Biomakers Prev., 8, 507-512.
127. Lightfoot, T. J., Cupid, B. C., Nicholson, S., Leveson, S. H., Alexander, D. J. and Garner, R. C. (2001) The use of accelerator mass spectrometry in cancer risk assessment following dietary exposure to heterocyclic amines and polycyclic aromatic hydrocarbons. Toxicology, 168, 89-90.
128. Chen, G. P., Zhang, D. Q., Jing, N., Yin, S. H., Falany, C. N. and Radominska-Pandya, A. (2003) Human gastrointestinal sulfotransferases: Identification and distribution. Toxicol. Appl. Pharmacol., 187, 186-197.
129. Goetz, M. P., Rae, J. M., Suman, V. J. et al. (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol., 23, 9312-9318.
130. Punglia, R. S., Burstein, H. J., Winer, E. P. and Weeks, J. C. (2008) Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J. Natl Cancer Inst., 100, 642-648.
131. Dezentjé, V. O., Guchelaar, H.-J., Nortier, J. W. R., van de Velde, C. J. H. and Gelderblom, H. (2009) Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin. Cancer Res., 15, 15-21.
132. Chu, W., Fyles, A., Sellers, E. M., McCready, D. R., Murphy, J., Pal, T. and Narod, S. A. (2007) Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. Carcinogenesis, 28, 2139-2142.
133. Blevins-Primeau, A. S., Sun, D., Chen, G., Sharma, A. K., Gallagher, C. J., Amin, S. and Lazarus, P. (2009) Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res., 69, 1892-1900.
134. Terashima, I., Suzuki, N. and Shibutani, S. (1999) Mutagenic potential of a-(N2-deoxyguanosinyl)tamoxifen lesions, the major DNA adduct detected in endometrial tissues of patients treated with tamoxifen. Cancer Res., 59, 2091-2095.
135. Shibutani, S. and Dasaradhi, L. (1997) Miscoding potential of tamoxifenderived DNA adducts: a-(N2-deoxyguanosinyl)tamoxifen. Biochemistry, 36, 13010-13017.
136. Yasui, M., Suzuki, N., Laxmi, Y. R. S. and Shibutani, S. (2006) Translesion synthesis past tamoxifen-derived DNA adducts by human DNA polymerases eta and kappa. Biochemistry, 45, 12167-12174.
137. McLuckie, K. I. E., Routledge, M. N., Brown, K., Gaskell, M., Farmer, P. B., Roberts, G. C. K. and Martin, E. A. (2002) DNA adducts formed from 4-hydroxytamoxifen are more mutagenic than those formed by a-acetoxytamoxifen in a shuttle vector target gene replicated in human Ad293 cells. Biochemistry, 41, 8899-8906.
138. Liapis, E., McLuckie, K. I. E., Lewis, P. D., Farmer, P. B. and Brown, K. (2008) Mutagenicity of tamoxifen DNA adducts in human endometrial cells and in silico prediction of p53 mutation hotspots. Nucleic Acids Res., 36, 5933-5945.
139. McLuckie, K. I. E., Crookston, R. J., Gaskell, M., Farmer, P. B., Routledge, M. N., Martin, E. A. and Brown, K. (2005) Mutation spectra induced by a-acetoxytamoxifen-DNA adducts in human DNA repair proficient and deficient (Xeroderma pigmentosum complementation group A) cells. Biochemistry, 44, 8198-8205.
140. Shibutani, S., Reardon, J. T., Suzuki, N. and Sancar, A. (2000) Excision of tamoxifen-DNA adducts by the human nucleotide excision repair system. Cancer Res., 60, 2607-2610.
141. Mizutani, A., Okada, T., Shibutani, S., Sonoda, E., Hochegger, H., Nishigori, C., Miyachi, Y., Takeda, S. and Yamazoe, M. (2004) Extensive chromosomal breaks are induced by tamoxifen and estrogen in DNA repair-deficient cells. Cancer Res., 64, 3144-3147.
142. Laxmi, Y. R. S., Suzuki, N., Kim, S. Y. and Shibutani, S. (2004) Synthesis of oligodeoxynucleotides containing a single diastereoisomer of a-(N2-2#-deoxyguanosinyl)-N-desmethyltamoxifen. Bioorg. Med. Chem. Lett., 14, 4051-4054.
143. Lunn, R. M., Zhang, Y. J., Wang, L. Y., Chen, C. J., Lee, P. H., Lee, C. S., Tsai, W. Y. and Santella, R. M. (1997) p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Res., 57, 3471-3477.
144. Grollman, A. P., Shibutani, S., Moriya, M. et al. (2007) Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc. Natl Acad. Sci. U.S.A., 104, 12129-12134.
145. Lewis, P. D. and Parry, J. M. (2004) In silico p53 mutation hotspots in lung cancer. Carcinogenesis, 25, 1099-1107.
146. Fujiwara, K., Enomoto, T., Fujita, M. et al. (2008) Alterations of the Kras and p53 genes in tamoxifen-associated endometrial carcinoma. Oncol. Rep., 19, 1293-1298.
147. Enomoto, T., Fujita, M., Inoue, M., Nomura, T. and Shroyer, K. R. (1995) Alterations of the p53 tumor suppressor gene and activation of c-K-ras-2 protooncogene in endometrial adenocarcinoma from Colorado. Am. J. Clin. Pathol., 103, 224-230.
148. Dowsett, M. and Howell, A. (2002) Breast cancer: aromatase inhibitors take on tamoxifen. Nat. Med., 8, 1341-1344.
149. Vogel, V. G., Costantino, J. P., Wickerham, D. L. et al. (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA, 295, 2727-2741.
150. Jordan, V. C. (2006) Optimising endocrine approaches for the chemoprevention of breast cancer: beyond the Study of Tamoxifen and Raloxifene (STAR) Trial. Eur. J. Cancer, 42, 2909-2913.
151. Shang, Y. (2006) Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat. Rev. Cancer, 6, 360-368.
152. Umemoto, A., Lin, C.-X., Ueyama, Y., Komaki, K., Laxmi, Y. R. S. and Shibutani, S. (2006) Absence of DNA adduct in the leukocytes from breast cancer patients treated with toremifene. Chem. Res. Toxicol., 19, 421-425.